II. Definitions
- Androgenic Alopecia (Male-patterned Baldness)
- Non-scarring androgen related Alopecia
III. Epidemiology
- Most common type of Alopecia (esp. white men)
- Hereditary trait (positive Family History)
- Increasing Incidence with age
- Affects white men 30% at age 30, 40% at age 40, 50% at age 50 years
- Affects up to 38% of women over age 70 years
IV. Course
V. Pathophysiology
- Androgen exposure shortens Hair FollicleAnagen phase
- Men with increased androgen levels
- Women with increased 5a-reductase, androgen receptors
- Affected Hair Follicles transition to vellus follicles
- Hair becomes shorter, finer, and less pigmented
- Progresses with each successive cycle
- Related to higher Dihydrotestosterone (DHT) levels
- Testosterone is converted to Dihydrotestosterone (DHT) by the enzyme 5 alpha-reductase (5AR)
- Hair Follicles transition from terminal follicles to vellus follicles in response to DHT receptor binding
- Androgen receptor density and 5AR activity are increased in genetically predisposed patients
VI. Symptoms
- Gradual progression of Hair Loss
VII. Signs
-
General
- Hair Follicles in affected regions are vellus follicles, appearing miniaturized
- Men (M-Type distribution)
- Hair Loss affecting temples (bitemporal), frontal forehead and crown (vertex)
- Sides and back are spared
- Women
- Central and vertex scalp thinning
- Temples and frontal scalp are spared unlike the M-Type found in men
VIII. Differential Diagnosis
IX. Grading: Rating of Hair Loss (Norwood and Hamilton Scale)
- Type I: Minimal hair line recession
- Type II: Symmetrical triangular Hair Loss over temples
- Type III: More Hair Loss at vertex and less at temple
- Type IV-V: Temple and vertex Hair Loss; some crown loss
- Type VI: Contiguous frontal, vertex, and crown baldness
- Type VII: Hair remains only over ears and occiput
- References
- Hamilton (1951) Ann NY Acad Dermatol 53:708-28
- Norwood (1975) South Med J 68(11):1359-65 [PubMed]
X. Labs: Women with Androgenetic Alopecia
- Indications (Not required in most cases)
- Irregular Menses
- Sudden Hair Loss
- Hirsutism
- New onset Acne Vulgaris
- Infertility
- Lab tests
XI. Management
- Precautions
- Medications for Women
- Avoid all Hair Loss medications during pregnancy
- Topical Minoxidil (Rogaine, Hers) 2%
- Preferred first line agent in female pattern Hair Loss
- Apply 2% solution topically twice daily (or 5% foam once daily) to dry scalp (not hair)
- Risk of Hypertrichosis of the face
- Expect initial hair shedding on starting
- Expect 4 months to see any benefit (and 12 months to see full effect)
- Retin-A may augment effect (experimental)
- Apply at different time of day
- Oral Contraceptives
- Less effective than Minoxidil
- Choose OCP with low Progestin Androgenic Activity
- Norgestimate (e.g. Ortho Tri-Cyclen)
- Norethindrone (e.g. Modicon)
- Spironolactone
- Variable efficacy - results in modest reduction in Hair Loss
- Dose: 100 to 200 mg orally daily in divided doses
- Flutamide (Eulexin)
- Dose: 250 mg orally daily
- Liver function abnormalities occur in up to one third of patients
- Avoid agents without efficacy in women
- Finasteride is ineffective in women
- Supplements (e.g. Nutrafol, Viviscal, Biotin, Collagen, zinc) lack evidence to support their use
- Medications for Men
- Finasteride (Propecia)
- Dose: 1 mg orally daily
- Consider prescribing one quarter tablet daily of the 5 mg tablet (generic, cheap)
- 5-alpha reductase inhibitor indicated for men only, and if Topical Minoxidil ineffective
- Oral preparation for vertex or frontal balding
- Modifies serum PSA levels (upper limit of normal may be twice that of those not on Finasteride)
- Caution patients regarding risk of Suicidal Ideation, Sexual Dysfunction with Finasteride
- May help detect high grade Prostate Cancers earlier
- Dose: 1 mg orally daily
- Minoxidil (Rogaine) 2% solution or 5% foam
- Most effective for vertex balding (than in frontal area), and effects are delayed 6-12 months
- Applied topically (1 ml) twice daily to dry scalp
- Expect initial hair shedding on starting
- Ketoconazole 2% Shampoo (Nizoral)
- Shampoo 2-4 times weekly
- Unknown efficacy and not FDA approved for Androgenetic Alopecia
- Pyrithione Zinc (1%)
- Shampoo 2-4 times weekly
- Unknown efficacy and not FDA approved for Androgenetic Alopecia
- Finasteride (Propecia)
-
Hair Transplant
- Looks better in photos
- Better in curly haired persons
- Laser devices (Restore Caps, HairMax Combs)
- Marginally effective at slowing Hair Loss and promoting Hair Growth
-
Platelet Rich Plasma Injection
- Improves hair density in men better than Minoxidil, Finasteride and Bimatroprost
- Less effective than low level laser therapy
- No reported serious adverse events
- Georgiadis (2022) am fam Physician 105(1): 84-5 [PubMed]
- Avoid ineffective or unproven measures
- Avoid topical oils
- Avoid oral supplements for Alopecia (Biotin, keratin, Saw Palmetto, zinc)
XII. References
- (2021) Presc Lett 28(11): 65
- (2023) Presc Lett 30(3): 18
- Drake (1996) J Am Acad Dermatol 35:465-9 [PubMed]
- Phillips (2017) Am Fam Physician 96(6): 371-8 [PubMed]
- Scow (1999) Am Fam Physician, 59(8):2189-94 [PubMed]
- Springer (2003) Am Fam Physician 68(1):93-102 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
Concepts | Disease or Syndrome (T047) |
MSH | D000505 |
ICD10 | L64 , L64.9 |
SnomedCT | 238726003, 333111000009102, 87872006, 201144006 |
English | Alopecia, Androgenetic, Alopecia, Male Pattern, Male Pattern Baldness, Male Pattern Alopecia, Androgenic alopecia, unspecified, ANDROGENETIC ALOPECIA, AGA, MPB, Androgenetic Alopecia, ALOPECIA ANDROGENET, ANDROGENET ALOPECIA, BALDNESS, MALE PATTERN, male pattern baldness (physical finding), male pattern baldness, male-pattern baldness, alopecia androgenic, male pattern alopecia, baldness male pattern, alopecia androgenetic, androgenic alopecia, androgenetic alopecia, pattern baldness, Baldness, Male Pattern, androgenic alopecia (diagnosis), Pattern Baldness, Androgenic Alopecia, Female Pattern Baldness, Androgenic alopecia (disorder), Atrophic follicular dysplasia (finding), Atrophic follicular dysplasia, Male pattern alopecia, Common baldness, Hereditary alopecia, Alopecia hereditaria, Androgenetic alopecia, Male pattern baldness, Pattern baldness, Androgenic alopecia, Male pattern alopecia (disorder), Alopecia hereditaria (disorder), baldness; male-pattern, alopecia; androgenic, androgenic; alopecia |
French | Alopécie androgénétique, Alopécie androgénétique de l'homme, Alopécie androgénique, Alopécie de type masculin, Calvitie de type masculin, Alopécie androgénogénétique, Calvitie hippocratique |
German | Alopezie, androgenetische, Male-pattern Alopezie, androgene Alopezie, Alopecia androgenetica, nicht naeher bezeichnet, Alopecia androgenetica, Alopezie, männlicher Typ, Glatzenbildung vom männlichen Typ |
Spanish | Calvicie de tipo masculino, Alopecia androgénica, Alopecia androgénetica, alopecia andrógena, alopecia de distribución masculina (trastorno), alopecia de distribución masculina, alopecia hereditaria (trastorno), alopecia hereditaria, calvicie común, Alopecia Androgenética, Calvicie Masculina |
Italian | Calvizie maschile con distribuzione, Alopecia androgenica, Alopecia maschile, Calvizie maschile, Alopecia androgenetica |
Dutch | mannelijk kaalheidspatroon, androgenetische alopecie, androgene alopecie, alopecia; androgeen, androgeen; alopecia, kaalheid; mannelijk patroon, Alopecia androgenetica, niet gespecificeerd, 'Male pattern'-kaalheid, Alopecia androgenetica |
Portuguese | Alopécia androgenética masculina, Alopécia androgénica, Alopécia androgenética, Alopecia Androgênica, Calvície Padrão Masculino |
Japanese | ダンセイガタダツモウショウ, アンドロゲンセイダツモウショウ, アンドロゲン性脱毛症, 男性型脱毛症 |
Czech | Plešatost mužského typu, Androgenetická alopecie, Androgenní alopecie, androgenetická alopecie |
Korean | 안드로젠성 탈모증, 상세불명의 안드로젠성 탈모증 |
Hungarian | Férfias jellegű kopaszság, Androgenetikus alopecia, Androgén alopecia |
Norwegian | Alopesi av mannlig type, Skallethet av mannlig type, Androgen alopesi, Alopecia androgenica |